A Multicenter, Double-Blind, Randomized, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants Less Than 3 Months of Age
Latest Information Update: 12 May 2022
At a glance
- Drugs Caspofungin (Primary) ; Amphotericin B
- Indications Invasive candidiasis
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 05 Oct 2019 Results published in the Journal of Antimicrobial Chemotherapy
- 07 Oct 2018 Results presented at the IDWeek 2018
- 06 Mar 2018 Status changed from active, no longer recruiting to discontinued.